PTGX · Protagonist Therapeutics, Inc.

Protagonist Therapeutics delivered a material turnaround in Q1 2026, reporting $3.8 million in net income—its first quarterly profit in recent history—compared to a $11.7 million loss in Q1 2025. This shift was overwhelmingly driven by $56.4 million in license and collaboration revenue, of which $50.0 million was a non-recurring milestone tied to the March 2026 FDA approval of ICOTYDE™ (icotrokinra) for plaque psoriasis, licensed to Janssen. The remaining $6.4 million reflected development services and cost reimbursements under the Takeda rusfertide collaboration. R&D expense rose 30% year-over-year to $46.7 million, reflecting increased investment in wholly-owned assets—including PN-881 and obesity programs—partially offset by reduced rusfertide Phase 3 trial costs. G&A expense also increased modestly, primarily due to higher personnel and stock-based compensation costs. Management highlighted the strategic inflection point: ICOTYDE’s commercial launch, rusfertide’s Priority Review status with an August 2026 PDUFA date, and the April 28, 2026 exercise of the rusfertide opt-out right—which unlocked immediate liquidity ($200M), enhanced long-term economics (14–29% royalties), and de-risked future revenue streams. With $620.3 million in cash as of March 31, 2026, the company affirmed a cash runway extending through at least 2028, enabling continued advancement of its clinical pipeline without near-term financing pressure. The press release explicitly frames these developments as foundational to 'near-, medium and long-term value creation'—underscoring the transition from R&D-stage biotech to a commercially engaged, milestone-and-royalty-supported enterprise.